1 / 10

miRNA -drug resistance mechanisms Summary

miRNA -drug resistance mechanisms Summary. Hypothesis: The interplay between miRNAs , signaling pathways and epigenetic and genetic alterations are responsible for the development of drug resistance. Copy Number Variations (CNVs). MicroRNAs. Signaling pathways. Epigenetics.

azia
Télécharger la présentation

miRNA -drug resistance mechanisms Summary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. miRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterationsare responsible for the development of drug resistance Copy Number Variations (CNVs) MicroRNAs Signalingpathways Epigenetics

  2. Tamoxifen resistance miRNA mRNA protein Methylation ChIP-seq ER+ Trastuzumab resistance: Dynamic analysis Trastuzumabsensitive ERBB2+ SKBr3 and BT474 Trastuzumab resistant 0 6 12 18 24 30 weeks DNA, RNA, miRNA, protein isolation miRNA, mRNA, protein, methylation analysis

  3. Aim 1:Classify miRNA, mRNA, protein expression and methylation status profile of tamoxifen and trastuzumab resistance phenotype to identify key molecular signatures as markers for resistance and treatment response.

  4. Previous work: Ward et al, Oncogene 2012 Unpublished data: Ward et al

  5. Aim 1:Classify miRNA, mRNA, protein expression and methylation status profile of tamoxifen and trastuzumab resistance phenotype to identify key molecular signatures as markers for resistance and treatment response. Aim 2:Identify early and late epigenetic and/or genetic changes during the process of trastuzumabresistance which can be used as a predictive marker for resistance development. Aim 3:Classify miRNA, mRNA, protein expression and methylation status profile of tamoxifen and trastuzumab resistance phenotype in metastasis compared to primary tumor in vivo (xenograft mouse models and patient samples?)

  6. Aim 1:Classify miRNA, mRNA, protein expression and methylation status profile of tamoxifen and trastuzumab resistance phenotype to identify key molecular signatures as markers for resistance and treatment response. Aim 2:Identify early and late epigenetic and/or genetic changes during the process of trastuzumabresistance which can be used as a predictive marker for resistance development. Aim 3:Classify miRNA, mRNA, protein expression and methylation status profile of tamoxifen and trastuzumab resistance phenotype in metastasis compared to primary tumor in vivo (xenograft mouse models and patient samples?) Aim 4:Identify biomarkers (e.g. circulating miRNAs) in the plasma of xenograft mouse models and breast cancer patients (?) as an early onset marker for resistance development

  7. Aim 5:Understand the molecular mechanisms what causes the alterations in the miRNA expression. Aim 6: Identify the molecular mechanisms how genetic and epigenetic changes are responsible for the development of tamoxifen and trastuzumab resistance phenotype in vitro and in vivo.

  8. Previous work: EMT: epithelial to mesenchymal transition MTDH: metadherin Ward et al, Oncogene 2012

  9. Aim 5:Understand the molecular mechanisms what causes the alterations in the miRNA expression. Aim 6: Identify the molecular mechanisms how genetic and epigenetic changes are responsible for the development of tamoxifen and trastuzumab resistance phenotype in vitro and in vivo. Aim 7: Identify and test new potential targets to overcome tamoxifen and trastuzumab resistance and find new strategies for breast cancer therapies. • e.g. combination with • signaling pathways inhibitor • miRNAs inhibitors • HDAC inhibitors…

  10. miRNA-drug resistance mechanisms Internal Networking Aim 3+4 Aim 7 Aim 3,4,6,7 Aim 1-3+5 Aim 3+7 Aim 2 Aim 6 Aim 6

More Related